Intracellular osteopontin regulates the lineage commitment of lymphoid subsets
US11371989B2 · kind B2 · utility
0Cited by
8References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 19, 2018 |
| Grant date | Jun 28, 2022 |
| Priority date | — |
| Expiry date | Apr 1, 2040 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for diagnosing and prognosing autoimmune diseases and T cell lymphomas are provided, for example by measuring levels of intracellular osteopontin (OPN-i). Also provided are screening methods for identifying activators and inhibitors of the transcription factor Bcl6, which is involved in T cell activation/differentiation. Other aspects of the disclosure provide methods for enhancing adoptive T cell transfer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.